Central Pacific Bank Trust Division Trims Stock Position in Danaher Corporation $DHR

Key Points

• Central Pacific Bank Trust Division reduced its stake in Danaher Corporation by 95.6%, owning only 198 shares after selling 4,315 shares during the second quarter.
• Danaher reported $1.80 earnings per share for the last quarter, exceeding analysts' expectations, with revenues of $5.94 billion, up 3.4% from the previous year.
• The company has announced a quarterly dividend of $0.32 per share, scheduled to be paid on October 31st, representing a 0.7% yield.

Central Pacific Bank Trust Division cut its stake in Danaher Corporation (NYSE:DHR - Free Report) by 95.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 198 shares of the conglomerate's stock after selling 4,315 shares during the period. Central Pacific Bank Trust Division's holdings in Danaher were worth $39,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GHP Investment Advisors Inc. lifted its position in Danaher by 396.0% in the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after acquiring an additional 99 shares during the last quarter. Heck Capital Advisors LLC purchased a new stake in shares of Danaher in the fourth quarter valued at about $27,000. Sierra Ocean LLC raised its holdings in shares of Danaher by 116.9% in the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after buying an additional 76 shares during the last quarter. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Danaher in the first quarter valued at about $31,000. Finally, Dunhill Financial LLC raised its holdings in shares of Danaher by 68.4% in the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after buying an additional 67 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Trading Down 2.6%

Shares of Danaher stock opened at $190.07 on Monday. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The company's 50-day simple moving average is $201.21 and its 200-day simple moving average is $198.78. The firm has a market cap of $136.10 billion, a price-to-earnings ratio of 40.44, a price-to-earnings-growth ratio of 2.65 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same period in the previous year, the business posted $1.72 earnings per share. The business's revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio is presently 27.23%.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 11.20% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently commented on DHR. Guggenheim reaffirmed a "buy" rating and issued a $250.00 target price on shares of Danaher in a report on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 target price on shares of Danaher in a report on Tuesday, September 2nd. Evercore ISI reduced their target price on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Finally, Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target on the stock in a research note on Friday, July 11th. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $246.35.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.